Jerome A. J. Becker

Jerome A. J. Becker

Auto-generated profile, based on publicly available information

Jerome A. J. Becker

Université de Tours, INSERM, Imaging Brain & Neuropsychiatry iBraiN U1253, Tours, France

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2009 in Physiological Reviews
Verified
Journal Article
Closed access
PDF file
JMJulie Le Merrer
Julie Le Merrer
JBJérôme A. J. Becker
Jérôme A. J. Becker
KBKatia Befort
Katia Befort
BKBrigitte L. Kieffer
Brigitte L. Kieffer
The opioid system consists of three receptors, mu, delta, and kappa, which are activated by endogenous opioid peptides processed from three protein precursors, proopiomelanocortin, proenkephalin, and prodynorphin. Opioid receptors are recruited in response to natural rewarding stimuli and drugs of abuse, and both endogenous opioids and their receptors are modified as addiction develops. Mechanisms whereby aberrant activation and modifications of the opioid system contribute to drug craving and relapse remain to be clarified. This review summarizes our present knowledge on brain sites where the endogenous opioid system controls hedonic responses and is modified in response to drugs of abuse in the rodent brain. We review 1) the latest data on the anatomy of the opioid system, 2) the consequences of local intracerebral pharmacological manipulation of the opioid system on reinforced behaviors, 3) the consequences of gene knockout on reinforced behaviors and drug dependence, and 4) the consequences of chronic exposure to drugs of abuse on expression levels of opioid system genes. Future studies will establish key molecular actors of the system and neural sites where opioid peptides and receptors contribute to the onset of addictive disorders. Combined with data from human and nonhuman primate (not reviewed here), research in this extremely active field has implications both for our understanding of the biology of addiction and for therapeutic interventions to treat the disorder.

1 May 2009 in PLOS ONE
Verified
Journal Article
Open access
PDF file
APAmynah A. A. Pradhan
Amynah A. A. Pradhan
JBJérôme A. J. Becker
Jérôme A. J. Becker
GSGrégory Scherrer
Grégory Scherrer
PTPetra Tryoen-Toth
Petra Tryoen-Toth
DFDominique Filliol
Dominique Filliol
BKBrigitte L. Kieffer
Brigitte L. Kieffer
GPCRs regulate a remarkable diversity of biological functions, and are thus often targeted for drug therapies. Stimulation of a GPCR by an extracellular ligand triggers receptor signaling via G proteins, and this process is highly regulated. Receptor activation is typically accompanied by desensitization of receptor signaling, a complex feedback regulatory process of which receptor internalization is postulated as a key event. The in vivo significance of GPCR internalization is poorly understood. In fact, the majority of studies have been performed in transfected cell systems, which do not adequately model physiological environments and the complexity of integrated responses observed in the whole animal. In this study, we used knock-in mice expressing functional fluorescent delta opioid receptors (DOR-eGFP) in place of the native receptor to correlate receptor localization in neurons with behavioral responses. We analyzed the pain-relieving effects of two delta receptor agonists with similar signaling potencies and efficacies, but distinct internalizing properties. An initial treatment with the high (SNC80) or low (AR-M100390) internalizing agonist equally reduced CFA-induced inflammatory pain. However, subsequent drug treatment produced highly distinct responses. Animals initially treated with SNC80 showed no analgesic response to a second dose of either delta receptor agonist. Concomitant receptor internalization and G-protein uncoupling were observed throughout the nervous system. This loss of function was temporary, since full DOR-eGFP receptor responses were restored 24 hours after SNC80 administration. In contrast, treatment with AR-M100390 resulted in retained analgesic response to a subsequent agonist injection, and ex vivo analysis showed that DOR-eGFP receptor remained G protein-coupled on the cell surface. Finally SNC80 but not AR-M100390 produced DOR-eGFP phosphorylation, suggesting that the two agonists produce distinct active receptor conformations in vivo which likely lead to differential receptor trafficking. Together our data show that delta agonists retain full analgesic efficacy when receptors remain on the cell surface. In contrast, delta agonist-induced analgesia is abolished following receptor internalization, and complete behavioral desensitization is observed. Overall these results establish that, in the context of pain control, receptor localization fully controls receptor function in vivo. This finding has both fundamental and therapeutic implications for slow-recycling GPCRs.

12 September 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RWRaphaël Weibel
Raphaël Weibel
DRDavid Reiss
David Reiss
LKLaurie Karchewski
Laurie Karchewski
OGOlivier Gardon
Olivier Gardon
AMAudrey Matifas
Audrey Matifas
CGClaire Gaveriaux-Ruff
Claire Gaveriaux-Ruff
Opiates are powerful drugs to treat severe pain, and act via mu opioid receptors distributed throughout the nervous system. Their clinical use is hampered by centrally-mediated adverse effects, including nausea or respiratory depression. Here we used a genetic approach to investigate the potential of peripheral mu opioid receptors as targets for pain treatment. We generated conditional knockout (cKO) mice in which mu opioid receptors are deleted specifically in primary afferent Nav1.8-positive neurons. Mutant animals were compared to controls for acute nociception, inflammatory pain, opiate-induced analgesia and constipation. There was a 76% decrease of mu receptor-positive neurons and a 60% reduction of mu-receptor mRNA in dorsal root ganglia of cKO mice. Mutant mice showed normal responses to heat, mechanical, visceral and chemical stimuli, as well as unchanged morphine antinociception and tolerance to antinociception in models of acute pain. Inflammatory pain developed similarly in cKO and controls mice after Complete Freund’s Adjuvant. In the inflammation model, however, opiate-induced (morphine, fentanyl and loperamide) analgesia was reduced in mutant mice as compared to controls, and abolished at low doses. Morphine-induced constipation remained intact in cKO mice. We therefore genetically demonstrate for the first time that mu opioid receptors partly mediate opiate analgesia at the level of Nav1.8-positive sensory neurons. In our study, this mechanism operates under conditions of inflammatory pain, but not nociception. Previous pharmacology suggests that peripheral opiates may be clinically useful, and our data further demonstrate that Nav1.8 neuron-associated mu opioid receptors are feasible targets to alleviate some forms of persistent pain.

12 March 2014 in Neuropsychopharmacology
Verified
Journal Article
Closed access
JBJérôme Aj Becker
Jérôme Aj Becker
DCDaniel Clesse
Daniel Clesse
CSCoralie Spiegelhalter
Coralie Spiegelhalter
YSYannick Schwab
Yannick Schwab
JMJulie Le Merrer
Julie Le Merrer
BKBrigitte L Kieffer
Brigitte L Kieffer

27 May 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
RTRicardos Tabet
Ricardos Tabet
EMEnora Moutin
Enora Moutin
JBJérôme A. J. Becker
Jérôme A. J. Becker
DHDimitri Heintz
Dimitri Heintz
LFLaetitia Fouillen
Laetitia Fouillen
HMHervé Moine
Hervé Moine
Significance: Fragile X syndrome (FXS), the most frequent form of inherited intellectual disability, is caused by the absence of the protein Fragile X Mental Retardation Protein (FMRP) in neurons. In the absence of FMRP, the translation of a high number of mRNAs is increased in glutamatergic synapses, leading to abnormal synaptic function. It is unclear whether FMRP individually controls each of these mRNAs and whether some mRNAs are more important for the pathology. This study shows that FMRP mostly associates with and controls one main mRNA target in neurons, diacylglycerol kinase kappa (Dgkκ), a master regulator that controls two key signaling pathways activating protein synthesis. The deregulation of Dgkκ could account for many of the symptoms associated with FXS and could represent a novel therapeutic target.

4 May 2017 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
LPLucie P Pellissier
Lucie P Pellissier
JGJorge Gandía
Jorge Gandía
TLThibaut Laboute
Thibaut Laboute
JBJérôme A J Becker
Jérôme A J Becker
JMJulie Le Merrer
Julie Le Merrer